Table 1.
Summary of baseline TFI/DFI
| PALOMA-2 | Palbociclib + letrozole
(n = 277) |
Placebo + letrozole (n = 141) |
|---|---|---|
| TFI, n (%) | ||
| ≤ 1 year | 98 (35.4) | 48 (34.0) |
| > 1‒2 years | 25 (9.0) | 16 (11.3) |
| > 2‒5 years | 64 (23.1) | 31 (22.0) |
| > 5 years | 90 (32.5) | 46 (32.6) |
| Duration of TFI, months | ||
| Mean (SD) | 50.2 (59.9) | 55.6 (69.9) |
| Median (range) | 37.1 (− 10.7 to 337.5) | 30.9 (− 3.6 to 332.7) |
| PALOMA-3 | Palbociclib + fulvestrant (n = 232) |
Placebo + fulvestrant (n = 123) |
|---|---|---|
| DFI, n (%) | ||
| ≤ 1 year | 10 (4.3) | 3 (2.4) |
| > 1‒2 years | 30 (12.9) | 19 (15.4) |
| > 2‒5 years | 101 (43.5) | 49 (39.8) |
| > 5‒10 years | 53 (22.8) | 34 (27.6) |
| > 10 years | 37 (15.9) | 18 (14.6) |
| Duration of DFI, months | ||
| Mean (SD) | 65.9 (54.0) | 69.6 (57.4) |
| Median (range) | 49.2 (0.03‒277.9) | 52.0 (2.8‒326.4) |
TFI was defined as the time between the end of any (neo)adjuvant therapy and relapse in PALOMA-2, and DFI was defined as the time between the first diagnosis of breast cancer and disease recurrence in PALOMA-3
DFI disease-free interval, TFI treatment-free interval